Michael E. Faerm
Direttore Finanziario/CFO presso VIRACTA THERAPEUTICS, INC.
Posizioni attive di Michael E. Faerm
Società | Posizione | Inizio | Fine |
---|---|---|---|
VIRACTA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 13/05/2024 | - |
Direttore Finanziario/CFO | 13/05/2024 | - |
Storia della carriera di Michael E. Faerm
Precedenti posizioni note di Michael E. Faerm
Società | Posizione | Inizio | Fine |
---|---|---|---|
HARPOON THERAPEUTICS, INC. | Direttore Finanziario/CFO | 01/10/2023 | 01/03/2024 |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Direttore Finanziario/CFO | 01/04/2021 | 01/03/2023 |
INNOVIVA, INC. | Corporate Officer/Principal | 01/07/2015 | 07/02/2018 |
FOREST LABORATORIES, INC. | Corporate Officer/Principal | 01/01/2006 | 01/01/2006 |
REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/10/2004 | 01/10/2004 |
Merrill Lynch & Co., Inc. | Corporate Officer/Principal | 31/12/2000 | 31/12/2000 |
Wells Fargo Securities LLC
Wells Fargo Securities LLC Investment ManagersFinance Wells Fargo Securities LLC (WFS) is the broker/dealer subsidiary of EVEREN Capital Corp., ultimately owned by Wells Fargo & Co. (NYSE: WFC). Headquartered in New York, WFS delivers a comprehensive suite of banking, capital markets and advisory solutions, such as a full complement of sales, trading and research capabilities, to corporate, government and institutional clients. | Analyst-Equity | 01/06/2013 | - |
Credit Suisse Securities (USA) LLC (Broker)
Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Credit Suisse Securities (USA) LLC (Credit Suisse Securities USA) is the broker/dealer division of Credit Suisse Securities (USA) LLC, an investment banking company headquartered in New York City. The firm was founded in 1998 and is a wholly owned subsidiary of Credit Suisse (USA), Inc., ultimately owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Securities USA offers a suite of equities, solutions and credit products and services which includes global securities sales, trading and execution, prime brokerage and comprehensive investment research. Their clients include financial institutions, corporations, governments, institutional investors, such as pension funds and hedge funds, and private individuals around the world. | Analyst-Equity | 01/01/2006 | - |
Formazione di Michael E. Faerm
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Stanford University | Graduate Degree |
Harvard Business School | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 13 |
Posizioni
Corporate Officer/Principal | 4 |
Director of Finance/CFO | 3 |
Analyst-Equity | 2 |
Settori
Health Technology | 7 |
Finance | 4 |
Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
REGENERON PHARMACEUTICALS, INC. | Health Technology |
INNOVIVA, INC. | Health Technology |
VIRACTA THERAPEUTICS, INC. | Health Technology |
Aziende private | 6 |
---|---|
Credit Suisse Securities (USA) LLC (Broker)
Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Credit Suisse Securities (USA) LLC (Credit Suisse Securities USA) is the broker/dealer division of Credit Suisse Securities (USA) LLC, an investment banking company headquartered in New York City. The firm was founded in 1998 and is a wholly owned subsidiary of Credit Suisse (USA), Inc., ultimately owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Securities USA offers a suite of equities, solutions and credit products and services which includes global securities sales, trading and execution, prime brokerage and comprehensive investment research. Their clients include financial institutions, corporations, governments, institutional investors, such as pension funds and hedge funds, and private individuals around the world. | Finance |
Merrill Lynch & Co., Inc. | Finance |
Forest Laboratories, Inc.
Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Wells Fargo Securities LLC
Wells Fargo Securities LLC Investment ManagersFinance Wells Fargo Securities LLC (WFS) is the broker/dealer subsidiary of EVEREN Capital Corp., ultimately owned by Wells Fargo & Co. (NYSE: WFC). Headquartered in New York, WFS delivers a comprehensive suite of banking, capital markets and advisory solutions, such as a full complement of sales, trading and research capabilities, to corporate, government and institutional clients. | Finance |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Health Technology |
Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Michael E. Faerm
- Esperienza